NasdaqCM:MEIP

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer.


Snowflake Analysis

Flawless balance sheet with high growth potential.

Share Price & News

How has MEI Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MEIP's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

19.4%

MEIP

0.7%

US Biotechs

1.8%

US Market


1 Year Return

12.9%

MEIP

22.1%

US Biotechs

3.7%

US Market

Return vs Industry: MEIP underperformed the US Biotechs industry which returned 22.1% over the past year.

Return vs Market: MEIP exceeded the US Market which returned 3.7% over the past year.


Shareholder returns

MEIPIndustryMarket
7 Day19.4%0.7%1.8%
30 Day50.6%4.9%5.6%
90 Day59.5%10.7%-7.4%
1 Year12.9%12.9%23.3%22.1%6.1%3.7%
3 Year65.6%65.6%36.3%31.7%28.3%19.8%
5 Year82.8%82.8%-2.5%-8.3%52.4%35.1%

Price Volatility Vs. Market

How volatile is MEI Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MEI Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MEIP ($3.51) is trading below our estimate of fair value ($33.12)

Significantly Below Fair Value: MEIP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MEIP is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: MEIP is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MEIP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MEIP is overvalued based on its PB Ratio (5x) compared to the US Biotechs industry average (3.8x).


Next Steps

Future Growth

How is MEI Pharma forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

59.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MEIP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: MEIP is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MEIP's is expected to become profitable in the next 3 years.

Revenue vs Market: MEIP's revenue (56.3% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: MEIP's revenue (56.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MEIP's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has MEI Pharma performed over the past 5 years?

-2.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MEIP is currently unprofitable.

Growing Profit Margin: MEIP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MEIP is unprofitable, and losses have increased over the past 5 years at a rate of -2.9% per year.

Accelerating Growth: Unable to compare MEIP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MEIP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: MEIP has a negative Return on Equity (-32.87%), as it is currently unprofitable.


Next Steps

Financial Health

How is MEI Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: MEIP's short term assets ($95.4M) exceed its short term liabilities ($10.3M).

Long Term Liabilities: MEIP's short term assets ($95.4M) exceed its long term liabilities ($11.9M).


Debt to Equity History and Analysis

Debt Level: MEIP is debt free.

Reducing Debt: MEIP has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MEIP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MEIP has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 9.3% each year.


Next Steps

Dividend

What is MEI Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MEIP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MEIP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MEIP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MEIP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MEIP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.9yrs

Average management tenure


CEO

Dan Gold (65yo)

10.08yrs

Tenure

US$1,854,414

Compensation

Dr. Daniel P. Gold, also known as Dan, Ph.D. has been the Chief Executive Officer and President of MEI Pharma, Inc. (Alternate Name: Marshall Edwards Inc.), a subsidiary of Novogen Limited since April 26,  ...


CEO Compensation Analysis

Compensation vs Market: Dan's total compensation ($USD1.85M) is about average for companies of similar size in the US market ($USD2.29M).

Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Daniel Gold
President10.08yrsUS$1.85m0.34% $1.3m
Brian Drazba
CFO & Secretary3.08yrsUS$842.61k0.035% $131.6k
David Urso
COO & General Counsel1.83yrsUS$1.31m0.023% $84.6k
Robert Mass
Chief Medical Officer8.92yrsUS$674.28k0.032% $118.2k
David Walsey
Vice President of IR & Corporate Communicationsno datano datano data
Karen Potts
Senior Vice President of Regulatory Affairs5.58yrsno datano data
Richard Ghalie
Senior Vice President of Clinical Development4.17yrsno datano data

4.9yrs

Average Tenure

59.5yo

Average Age

Experienced Management: MEIP's management team is considered experienced (4.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Daniel Gold
President10.08yrsUS$1.85m0.34% $1.3m
Tamar Howson
Independent Non-Executive Director0.83yrno datano data
Frederick Driscoll
Independent Non-Executive Director2.25yrsUS$158.94k0.059% $219.4k
Nicholas Glover
Independent Non-Executive Director6.92yrsUS$166.44kno data
Kevan Clemens
Independent Non Executive Director5.42yrsUS$161.44kno data
Christine White
Independent Non-Executive Chairman4.42yrsUS$183.94k0.014% $52.6k
Thomas Reynolds
Independent Non-Executive Director7.25yrsUS$161.44k0.0094% $35.1k
Charles Baltic
Independent Non-Executive Director8.58yrsUS$168.94k0.028% $103.9k
Cheryl Cohen
Non-Executive Director0.083yrno datano data

5.4yrs

Average Tenure

65yo

Average Age

Experienced Board: MEIP's board of directors are considered experienced (5.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48.7%.


Top Shareholders

Company Information

MEI Pharma, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MEI Pharma, Inc.
  • Ticker: MEIP
  • Exchange: NasdaqCM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$372.055m
  • Shares outstanding: 106.00m
  • Website: https://www.meipharma.com

Number of Employees


Location

  • MEI Pharma, Inc.
  • 3611 Valley Centre Drive
  • Suite 500
  • San Diego
  • California
  • 92130
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MEIPNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDDec 2003
MMIADB (Deutsche Boerse AG)YesCommon StockDEEURDec 2003
0JW9LSE (London Stock Exchange)YesCommon StockGBUSDDec 2003

Biography

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company’s clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory follicular lymphoma and B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor for B-cell malignancies and AML. In addition, the company engages in the development of ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex for the treatment of HER2-negative breast cancer. MEI Pharma, Inc. has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacture, and commercialization of Pracinostat; and a license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor, as well as related compounds. The company also has a license agreement with CyDex Pharmaceuticals, Inc. for Captisol to use with ME-344, which are isoflavone-based drug compounds; a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of ME-401 in combination with BeiGene’s zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies; and a license agreement with Kyowa Kirin Co., Ltd. for ME-401. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/25 03:22
End of Day Share Price2020/05/22 00:00
Earnings2020/03/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.